A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR).

J, Patel; D, Bass; A, Beishuizen; Ruiz X, Bocca; H, Boughanmi; A, Cahn; H, Colombo; GJ, Criner; K, Davy; J, de-Miguel-Díez; PA, Doreski; S, Fernandes; B, François; A, Gupta; K, Hanrott; T, Hatlen; D, Inman; JD, Isaacs; E, Jarvis; N, Kostina; T, Kropotina; JC, Lacherade; D, Lakshminarayanan; P, Martinez-Ayala; C, McEvoy; F, Meziani; M, Monchi; S, Mukherjee; R, Muñoz-Bermúdez; J, Neisen; C, O'Shea; G, Plantefeve; L, Schifano; LE, Schwab; Z, Shahid; M, Shirano; JE, Smith; E, Sprinz; C, Summers; N, Terzi; MA, Tidswell; Y, Trefilova; R, Williamson; D, Wyncoll; M, Layton

doi:10.1183/13993003.01870-2021

Public

A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR).

Shared by NobleBlocks on Feb 2, 2023 • 12:00 AM UTC

Authors:

Patel J

Bass D

Beishuizen A

Abstract

Background Granulocyte-macrophage colony-stimulating factor (GM-CSF) and dysregulated myeloid cell responses are implicated in the pathophysiology and severity of COVID-19.Methods In this randomised, sequential, multicentre, placebo-controlled, double-blind study, adults aged 18-79 years (Part 1) or...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!